You just read:

U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C

News provided by

AbbVie

24 Apr, 2015, 05:45 BST